Breast cancer in systemic lupus.

Area of Science:

• Rheumatology
• Oncology
• Epidemiology

Background:

• Systemic lupus erythematosus (SLE) is associated with a reduced incidence of breast cancer compared to the general population.
• Understanding the factors influencing breast cancer risk in SLE patients is crucial for risk stratification and management.

Purpose of the Study:

• To evaluate demographic and clinical characteristics associated with breast cancer risk in a large cohort of SLE patients.
• To determine the influence of disease activity, autoantibody positivity, and medication use on breast cancer development in SLE.

Main Methods:

• A case-cohort study was conducted using a multi-center international SLE patient sample.
• Breast cancer hazard ratios (HR) were calculated, adjusting for SLE duration and considering time-dependent measures of anti-dsDNA positivity, disease activity, and drug exposures.

Main Results:

• The study included 86 SLE breast cancer cases and 4498 cancer-free SLE controls, with an average follow-up of 7.6 years.
• SLE breast cancer cases were more likely to be white and older at cohort entry compared to controls.
• No significant associations were found between breast cancer development and anti-dsDNA positivity, cumulative disease activity, or most drug exposures over time.

Conclusions:

• Older age at cohort entry was the primary factor associated with breast cancer in this SLE cohort.
• There was limited evidence that studied clinical factors, including disease activity and specific drug use, strongly drive breast cancer risk in SLE.
• Further research is warranted to identify factors contributing to the observed lower breast cancer risk in SLE patients.